For example, inhibition of GPX4 to enhance ferroptosis can increase the sensitivity of HCC to sorafenib [47], Epstein-Barr virus(EBV)-infected nasopharyngeal carcinoma to platinum [48], etc. But, because GPX4 is widely expressed in anti-tumor immune cells such as T cells, dendritic cells, and neutrophils and in immunosuppressive cells such as Tregs, non-selective targeting of GPX4 in preclinical cancer therapy may lead to immune side effects that suppress anti-tumor immunity. Here, GPX4 is linked to nasopharyngeal carcinoma.